London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Vernal keratoconjunctivitis

Poster Details

First Author: K.Jyothi INDIA

Co Author(s):    M. Menta Ravindra   V. Kesaraju   M. Aitharaju        

Abstract Details


To report a rare case of keratoconjunctivitis with tranta nodules all over the upper half of the cornea


Mamata Medical College and general Hospital, Khammam, Andhra Pradesh, India


A 8yr old male child , torch , snellen's visual acuity chart , slit lamp , fluorescein strip


8yr old male patient presented to our OPD with itching, redness, photophobia , watering both eyes on and off since 2yrs . Patient is a known case of vernal keratoconjunctivitis and is on fluorometholone and olopatidine which he used when symptomatic. On examination patient had minimal edema of both lids with gaint papillae on upper palpebral conjunctiva , limbal papillae and limbal trantas nodules are present in both eyes. Cornea of the right eye has macular opacity involving the upper half with superficial vascularization with gelatinous tranta like nodules dispersed all over the upper half . Cornea of left eye also has macular opacity with superficial vascularization. Rest of anterior segment with in normal limits both eyes. Vision in right eye is 6/12 and left eye is 6/6 . Patient is started on topical 0.1% cyclosporine drops.


All cases of vernal keratoconjunctivitis must be regularly followed up to prevent sight threatening complications . Trantas nodules which are usually limited to limbus may sometimes involve the whole cornea in severe cases Patients who are unresponsive or in whom allergic process progesses despite topical steroids , must be treated with topical cyclosporine 1% or tacrolimus 0.03% FINANCIAL INTEREST: NONE

Back to Poster listing